Aktieanalyser från populära analyshus

Senaste aktieanalyserna

Alisa Bank: Suffering from demand weakness - Evli

Analys | Evli

•

19 Jun 10:20

Alisa Bank: Suffering from demand weakness - Evli

Eniro Group: Reshaped and recharged – Eniro’s next chapter - Redeye

Redeye re-initiates coverage of marketing technology company Eniro Group, perceiving the company to ...

Hansa Biopharma: Easing the financial pressure and the ability to pursue substantial growth opportunities - Redeye

Verve Group: Directed share issue - Redeye

Redeye provides a comment on Verve’s announcement of a directed share issue which strengthens the co...

Camurus: Positive Results in POSITANO - Redeye

Biovica: Adding capital and market reach - Redeye

Biovica records SEK 2.3m in total net sales (22% above Q4 last year), and clinical sales increased b...

Prolight Diagnostics: Positive patient data and patent approval strengthen case for Psyros - Emergers

Scibase: Enters collaboration and conducts SEK30m directed issue - Redeye

Redeye comments on Scibase entering a collaboration and license agreement with Castle Biosciences an...

Cantargia: Loan Agreement of SEK50m - Redeye

Cantargia

Analys | ABG Sundal Collier

•

18 Jun 07:24

Svedbergs Group: Project recovery delayed in Sweden - ABG

Q2 report due 18 July Q2e net sales SEK 555m, EBITA SEK 79m We leave our FVR unchanged at SEK 44-59 ...

Kontigo Care: Feelgood deal cements platform for private market scale-up - Redeye

Episurf: Status update regarding FDA clearance of MTP implant - Redeye

Redeye comments on Episurf Medical’s latest update regarding the FDA clearance process for the compa...

Nokian Panimo: Brewing profitable growth - Evli

Alzinova: CRO selected for phase II study and new CSF data - Redeye

Redeye comments on Alzinova’s recent announcements of a strategic collaboration with Worldwide Clini...

Alligator Bioscience: Regulatory path to phase III cleared - Redeye

Isofol Medical: A comeback story in the making - Redeye

Redeye re-initiates coverage of Isofol Medical, a Swedish oncology biotech company targeting the mul...

Isofol Medical

Analys | ABG Sundal Collier

•

17 Jun 07:10

Embellence Group: Look for D2C comments, Q2 to be uneventful - ABG

Acarix: First fixed US reimbursement for CADscor secured - Redeye

Redeye endorses today’s news that Acarix has secured a fixed reimbursement of USD300 for the CADScor...

AlzeCure: Our comment on the announced rights issue - Redeye

Hexatronic: Q2 2025 Preview – FX hurting - Redeye

Redeye reduces its forecasts and Base Case in Hexatronic slightly on the back of FX and the revised ...

Hexatronic

Analys | Analysguiden

•

16 Jun 10:45

Grangex: Konturer börjar anas - Analysguiden

Moberg Pharma: A very promising Norwegian launch - Redeye

Moberg Pharma successfully launched Teclara in Sweden last year, and the early initial feedback from...

Kancera: Positive top-line results in KANDOVA study - Redeye

Powercell: Expanded partnership with Bosch targeting China - Redeye

Powercell and Robert Bosch GmbH extend their strategic partnership to address the rapidly growing Ch...

Fiskars: Q2 likely to be very weak - Nordea

Fiskars

Analys | ABG Sundal Collier

•

16 Jun 07:11

Byggmästaren: Partial exit of largest holding and positive revaluation - ABG

Bridgepoint invests in Safe Life Implied valuation +15% vs.

Byggmästare AJ Ahlström

Analys | Redeye

•

13 Jun 15:55

Magle Chemoswed: Considers bond issue - Redeye

AlzeCure Pharma: Positive FDA feedback regarding ACD440 in orphan disease - Redeye

Redeye comments on yesterday’s news that AlzeCure has received positive feedback from the FDA regard...

Fiskars: Severe profit warning due to rapid decline in demand - Nordea

Fiskars

Analys | ABG Sundal Collier

•

13 Jun 07:21

Ovzon: Here comes the sun - ABG

We raise '25e-'27e EBITDA by 35-40% on the recent SEK 1bn order 2025 will be a strong year: sales +1...

Ovzon

Föregående Nästa